Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

Pomalyst (pomalidomide) is a prescription drug that’s used to treat ... Pomalyst works to treat multiple myeloma in several ways: Pomalyst stops new cancer cells from forming by blocking the ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

The multiple myeloma pipeline consists primarily of new drugs with established mechanisms of action that aim to outcompete existing agents, including BCMA-targeting agents and IMiDs (Table 1).

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

"The developers expect to create Russia's first drug for multiple myeloma based on CAR-NK therapy. It is planned that the drug using the new technology will pass all the necessary clinical trials and ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, talks unmet need in ...